Actin-Like Protein 8 Promotes the Progression of Triple-Negative Breast Cancer via Activating PI3K/AKT/mTOR Pathway

被引:15
作者
Fan, Shaoxia [1 ]
Yan, Shen [1 ]
Yang, Yang [1 ]
Shang, Jian [1 ]
Hao, Min [1 ]
机构
[1] Dongying Peoples Hosp, Breast & Thyroid Surg, Dongying 257091, Shandong, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2021年 / 14卷
关键词
TNBC; ACTL8; proliferation; migration; invasion; PI3K/AKT/mTOR pathway;
D O I
10.2147/OTT.S291403
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: The purpose of this study was to investigate the function of actin-like protein 8 (ACTL8) on triple-negative breast cancer (TNBC) and its potential mechanisms. Methods: In our study, ACTL8 expression and the prognostic values of ACTL8 were evaluated via the dataset from the Cancer Genome Atlas (TCGA). At the same time, the expression of ACTL8 in TNBC cells was measured by Western blot and qRT-PCR. Then, the effects of ACTL8 on the growth and metastasis of TNBC were investigated by using 5-ethynyl-20-deoxyuridine (EdU), colony formation, flow cytometry, wound healing and transwell assays. Mechanistically, Western blot was performed to confirm the interaction between ACTL8 and phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway in TNBC. Results: ACTL8 expression was upregulated in TNBC and associated with the poor prognosis of TNBC. Silencing ACTL8 suppressed the proliferation, migration and invasion, also promoted the apoptosis in MDA-MB-231 and BT-549 cells. Moreover, we found that silencing ACTL8 could inhibit the activation of PI3K/AKT/mTOR signaling pathway in MDA-MB-231 and BT-549 cells. Meanwhile, the impact of silencing ACTL8 on the proliferation, apoptosis, migration and invasion was enhanced by PI3K/AKT/mTOR pathway inhibitor (Wortmannin) and reversed by PI3K/AKT/mTOR pathway activator (740Y-P). Conclusion: Our data demonstrated that ACTL8 may facilitate the proliferation, migration and invasion, while inhibiting apoptosis through activating PI3K/Akt/mTOR signaling pathway in TNBC.
引用
收藏
页码:2463 / 2473
页数:11
相关论文
共 27 条
  • [1] Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
    Abramson, Vandana G.
    Lehmann, Brian D.
    Ballinger, Tarah J.
    Pietenpol, Jennifer A.
    [J]. CANCER, 2015, 121 (01) : 8 - 16
  • [2] Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
    Balafoutas, Dimitrios
    zur Hausen, Axel
    Mayer, Sebastian
    Hirschfeld, Marc
    Jaeger, Markus
    Denschlag, Dominik
    Gitsch, Gerald
    Jungbluth, Achim
    Stickeler, Elmar
    [J]. BMC CANCER, 2013, 13
  • [3] Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy
    Braunstein, Lior Z.
    Taghian, Alphonse G.
    Niemierko, Andrzej
    Salama, Laura
    Capuco, Alexander
    Bellon, Jennifer R.
    Wong, Julia S.
    Punglia, Rinaa S.
    MacDonald, Shannon M.
    Harris, Jay R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (01) : 173 - 179
  • [4] XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
    Chen, Xi
    Iliopoulos, Dimitrios
    Zhang, Qing
    Tang, Qianzi
    Greenblatt, Matthew B.
    Hatziapostolou, Maria
    Lim, Elgene
    Tam, Wai Leong
    Ni, Min
    Chen, Yiwen
    Mai, Junhua
    Shen, Haifa
    Hu, Dorothy Z.
    Adoro, Stanley
    Hu, Bella
    Song, Minkyung
    Tan, Chen
    Landis, Melissa D.
    Ferrari, Mauro
    Shin, Sandra J.
    Brown, Myles
    Chang, Jenny C.
    Liu, X. Shirley
    Glimcher, Laurie H.
    [J]. NATURE, 2014, 508 (7494) : 103 - +
  • [5] Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
    Corti, Francesca
    Nichetti, Federico
    Raimondi, Alessandra
    Niger, Monica
    Prinzi, Natalie
    Torchio, Martina
    Tamborini, Elena
    Perrone, Federica
    Pruneri, Giancarlo
    Di Bartolomeo, Maria
    de Braud, Filippo
    Pusceddu, Sara
    [J]. CANCER TREATMENT REVIEWS, 2019, 72 : 45 - 55
  • [6] Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
    Costa, Ricardo L. B.
    Han, Hyo Sook
    Gradishar, William J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (03) : 397 - 406
  • [7] Dhodapkar Madhav V, 2003, Cancer Immun, V3, P9
  • [8] The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
    Engelman, Jeffrey A.
    Luo, Ji
    Cantley, Lewis C.
    [J]. NATURE REVIEWS GENETICS, 2006, 7 (08) : 606 - 619
  • [9] Targeting PI3K signalling in cancer: opportunities, challenges and limitations
    Engelman, Jeffrey A.
    [J]. NATURE REVIEWS CANCER, 2009, 9 (08) : 550 - 562
  • [10] MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance
    Gasparri, Maria Luisa
    Besharat, Zein Mersini
    Farooqi, Ammad Ahmad
    Khalid, Sumbul
    Taghavi, Katayoun
    Besharat, Raad Aris
    Sabato, Claudia
    Papadia, Andrea
    Panici, Pierluigi Benedetti
    Mueller, Michael David
    Ferretti, Elisabetta
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (12) : 2313 - 2318